Format

Send to

Choose Destination
Blood Cancer J. 2018 Oct 4;8(10):95. doi: 10.1038/s41408-018-0124-1.

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.

Author information

1
First Department of Radiology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. lmoulop@med.uoa.gr.
2
First Department of Radiology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
3
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
4
Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
5
Department of Radiology, Clinica Universidad de Navarra, Pamplona, Spain.
6
Department of Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
7
Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA.
8
Department of Hematology, University of Nantes Health Centre, Nantes, France.
9
Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain.
10
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
11
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
12
Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Outpatient Cancer Center, Los Angeles, CA, USA.
13
Department of Radiology, German Cancer Research Center, Heidelberg, Germany.

Abstract

Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.

PMID:
30287814
PMCID:
PMC6172202
DOI:
10.1038/s41408-018-0124-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center